Advanced search
Publication Cover
Expert Review of Vaccines Volume 2, 2003 - Issue 2
Submit an article Journal homepage
110
Views
20
CrossRef citations to date
0
Altmetric
Review

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine

Rinaldo Zurbriggen Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Ian C Metcalfe Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Reinhard Glück Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Jean-François Viret Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
&
Christian Moser Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
Pages 295-304 | Published online: 09 Jan 2014

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Kaori Sano, Akira Ainai, Tadaki Suzuki & Hideki Hasegawa. (2018) Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. Expert Review of Vaccines 17:8, pages 687-696.
Read now
Gregory M Glenn, David C Flyer, Larry R Ellingsworth, Sarah A Frech, David M Frerichs, Robert C Seid & Jianmei Yu. (2007) Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Review of Vaccines 6:5, pages 809-819.
Read now

Articles from other publishers (18)

E. Valli, A. J. Harriett, M. K. Nowakowska, R. L. Baudier, W. B. Provosty, Z. McSween, L. B. Lawson, Y. Nakanishi & E. B. Norton. (2019) LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice. Scientific Reports 9:1.
Crossref
Neal A. Halsey, Kawsar R. Talaat, Adena Greenbaum, Eric Mensah, Matthew Z. Dudley, Tina Proveaux & Daniel A. Salmon. (2015) The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine 33, pages F1-F67.
Crossref
C. McEntee, E.C. Lavelle & D.T. O’Hagan. 2015. Mucosal Immunology. Mucosal Immunology 1211 1231 .
Reinhild Klein, Douglas M. Templeton & Michael Schwenk. (2014) Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report). Pure and Applied Chemistry 86:10, pages 1573-1617.
Crossref
Michael Schotsaert & Adolfo García-Sastre. (2014) Influenza Vaccines: A Moving Interdisciplinary Field. Viruses 6:10, pages 3809-3826.
Crossref
Deborah L. Novicki, Jayanthi J. Wolf, Lisa M. Plitnick & Melanie Hartsough. 2014. The Role of the Study Director in Nonclinical Studies. The Role of the Study Director in Nonclinical Studies 439 463 .
Diana M. Alejo, Mauro P. Moraes, Xiaofen Liao, Camila C. Dias, Edan R. Tulman, Fayna Diaz-San Segundo, Debra Rood, Marvin J. Grubman & Lawrence K. Silbart. (2013) An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine 31:18, pages 2302-2309.
Crossref
Jayanthi J. Wolf. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics 243 255 .
Christian Moser & Mario Amacker. 2013. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines 287 307 .
O. Pérez, A. Batista-Duharte, E. González, C. Zayas, J. Balboa, M. Cuello, O. Cabrera, M. Lastre & V.E.J.C. Schijns. (2012) Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Brazilian Journal of Medical and Biological Research 45:8, pages 681-692.
Crossref
David J. M. Lewis, Zhiming Huo, Susan Barnett, Ingrid Kromann, Rafaela Giemza, Eva Galiza, Maria Woodrow, Birgit Thierry-Carstensen, Peter Andersen, Deborah Novicki, Giuseppe Del Giudice & Rino Rappuoli. (2009) Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin. PLoS ONE 4:9, pages e6999.
Crossref
Steven G. Reed, Sylvie Bertholet, Rhea N. Coler & Martin Friede. (2009) New horizons in adjuvants for vaccine development. Trends in Immunology 30:1, pages 23-32.
Crossref
Margaret Stanley, Lutz Gissmann & Denise Nardelli-Haefliger. (2008) Immunobiology of Human Papillomavirus Infection and Vaccination - Implications for Second Generation Vaccines. Vaccine 26, pages K62-K67.
Crossref
Barbara Rath, Thomas Linder, David Cornblath, Michael Hudson, Rohini Fernandopulle, Katharina Hartmann, Ulrich Heininger, Hector Izurieta, Leslie Killion, Pangiotis Kokotis, James Oleske, Michael Vajdy & Virginia Wong. (2007) “All that palsies is not Bell's [1]”—The need to define Bell's palsy as an adverse event following immunization. Vaccine 26:1, pages 1-14.
Crossref
Richard T. Kenney & Gregory M. Glenn. 2006. Immunopotentiators in Modern Vaccines. Immunopotentiators in Modern Vaccines 253 273 .
G. M. Glenn & R. T. Kenney. 2006. Mass Vaccination: Global Aspects — Progress and Obstacles. Mass Vaccination: Global Aspects — Progress and Obstacles 247 268 .
Frances Bowe, Ed C. Lavelle, Edel A. McNeela, Christine Hale, Simon Clare, Beatrice Arico, Marzia M. Giuliani, Aaron Rae, Alan Huett, Rino Rappuoli, Gordon Dougan & Kingston H. G. Mills. (2004) Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin . Infection and Immunity 72:7, pages 4052-4060.
Crossref
Gregory M Glenn, Richard T Kenney, Scott A Hammond & Larry R Ellingsworth. (2003) Transcutaneous immunization and immunostimulant strategies. Immunology and Allergy Clinics of North America 23:4, pages 787-813.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.